Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas

Journal of Leukocyte Biology

Volumn 76, Issue 2, 2004, Pages 322-332

  Mitsuhashi, Maki ^a,b   Liu, Jianguo ^a   Cao, Shanjin ^a   Shi, Xiaoyan ^a   Ma, Xiaojing ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Activated protein 1; Cytotoxic T lymphocyte; Macrophage; Natural killer cells; Tumor immunity

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 12; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROTEIN P35; PROTEIN P40; RECOMBINANT INTERLEUKIN 12; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; LUNG METASTASIS; MESSENGER RNA SYNTHESIS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN SECRETION; SPLEEN LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-12; ISOENZYMES; MACROPHAGES; MAMMARY NEOPLASMS, ANIMAL; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER;

ANIMALIA;

EID: 3442889057     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1203641     Document Type: Conference Paper

References (81)

1. Trinchieri, G. (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251-276.
2. Trinchieri, G., Scott, P. (1999) Interleukin-12: basic principles and clinical applications. Curr. Top. Microbiol. Immunol. 238, 57-78.
3. Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M., Sherman, M. L., Witmer, W. K., Rockwell, K. A., Shane, R. B., Lessin, S. R., Vonderheid, E. C. (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94, 902-908.
4. Rook, A. H., Zaki, M. H., Wysocka, M., Wood, G. S., Duvic, M., Showe, L. C., Foss, F., Shapiro, M., Kuzel, T. M., Olsen, E. A., Vonderheid, E. C., Laliberte, R., Sherman, M. L. (2001) The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann. N. Y. Acad. Sci. 941, 177-184.
5. Ansell, S. M., Witzig, T. E., Kurtin, P. J., Sloan, J. A., Jelinek, D. F., Howell, K. G., Markovic, S. N., Habermann, T. M., Klee, G. G., Atherton, P. J., Erlichman, C. (2002) Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99, 67-74.
6. Mortarini, R., Borri, A., Tragni, G., Bersani, I., Vegetti, C., Bajetta, E., Pilotti, S., Cerundolo, V., Anichini, A. (2000) Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res. 60, 3559-3568.
7. Gollob, J. A., Mier, J. W., Veenstra, K., McDermott, D. F., Clancy, D., Clancy, M., Atkins, M. B. (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6, 1678-1692.
8. Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., Weber, J. (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847.
9. Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S. S., Lee, M. H., Park, K., Kim, K., Jeong, H. S., Kim, J. A., Nam, S. J., Yang, J. H., Son, Y. I., Baek, C. H., Han, J., Ree, H. J., Lee, E. S., Kim, S. H., Kim, D. W., Ahn, Y. C., Huh, S. J., Choe, Y. H., Lee, J. H., Park, M. H., Kong, G. S., Park, E. Y., Kang, Y. K., Bang, Y. J., Paik, N. S., Lee, S. N., Kim, S. H., Kim, S., Robbins, P. D., Tahara, H., Lotze, M. T., Park, C. H. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12, 671-684.
10. Gajewski, T. F., Fallarino, F., Ashikari, A., Sherman, M. (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7, 895s-901s.
11. Portielje, J. E., Kruit, W. H., Schuler, M., Beck, J., Lamers, C. H., Stoter, G., Huber, C., de Boer-Dennert, M., Rakhit, A., Bolhuis, R. L., Aulitzky, W. E. (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5, 3983-3989.
12. Ma, X., Trinchieri, G. (2001) Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. 79, 55-92.
13. Handel-Fernandez, M. E., Cheng, X., Herbert, L. M., Lopez, D. M. (1997) Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol. 158, 280-286.
14. Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., van Damme, J., Mantovani, A. (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-κ B activation in tumor-associated macrophages. J. Immunol. 164, 762-767.
15. Elgert, K. D., Alleva, D. G., Mullins, D. W. (1998) Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64, 275-290.
16. Gong, J. H., Renz, H., Sprenger, H., Nain, M., Gemsa, D. (1990) Enhancement of tumor necrosis factor-α gene expression by low doses of prostaglandin E2 and cyclic GMP. Immunobiology 182, 44-55.
17. Ohmori, Y., Strassman, G., Hamilton, T. A. (1990) cAMP differentially regulates expression of mRNA encoding IL-1 a and IL-1 β in murine peritoneal macrophages. J. Immunol. 145, 3333-3339.
18. Williams, J. A., Shacter, E. (1997) Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase-1 and -2. J. Biol. Chem. 272, 25693-25699.
19. Vial, D., Arbibe, L., Havet, N., Dumarey, C., Vargaftig, B., Touqui, L. (1998) Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP. Biochem. J. 330, 89-94.
20. D'Acquisto, F., Sautebin, L., Iuvone, T., Di Rosa, M., Carnuccio, R. (1998) Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-κB activation in J774 macrophages. FEBS Lett. 440, 76-80.
21. Bennett, A., Charlier, E. M., McDonald, A. M., Simpson, J. S., Stamford, I. F., Zebro, T. (1977) Prostaglandins and breast cancer. Lancet 2, 624-626.
22. Bennett, A., Berstock, D. A., Raja, B., Stamford, I. F. (1979) Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers [proceedings]. Br. J. Pharmacol. 66, 451P.
23. Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., Toga, M. (1980) Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 64, 1061-1070.
24. Bennett, A., Stamford, I. F., Berstock, D. A., Dische, F., Singh, L., A'Hern, R. P. (1989) Breast cancer, prostaglandins and patient survival. Br. J. Cancer 59, 268-275.
25. van der Pouw Kraan, T. C., Boeije, L. C., Smeenk, R. J., Wijdenes, J., Aarden, L. A. (1995) Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181, 775-779.
26. Uotila, P. (1996) The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother. 43, 1-9.
27. Wu, C. Y., Wang, K., McDyer, J. F., Seder, R. A. (1998) Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161, 2723-2730.
28. Szabo, G., Girouard, L., Mandrekar, P., Catalano, D. (1998) Regulation of monocyte IL-12 production: augmentation by lymphocyte contact and acute ethanol treatment, inhibition by elevated intracellular cAMP. Int. J. Immunopharmacol. 20, 491-503.
29. Monteleone, G., Parrello, T., Monteleone, I., Tammaro, S., Luzza, F., Pallone, F. (1999) Interferon-γ (IFN-γ) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC). Clin. Exp. Immunol. 117, 469-475.
30. Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., Lee, J. C., Dubinett, S. M. (2000) Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361-370.
31. Harizi, H., Juzan, M., Grosset, C., Rashedi, M., Gualde, N. (2001) Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell. Immunol. 209, 19-28.
32. Harizi, H., Juzan, M., Pitard, V., Moreau, J. F., Gualde, N. (2002) Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 168, 2255-2263.
33. Narumiya, S., Sugimoto, Y., Ushikubi, F. (1999) Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79, 1193-1226.
34. Wright, D. H., Abran, D., Bhattacharya, M., Hou, X., Bernier, S. G., Bouayad, A., Fouron, J. C., Vazquez-Tello, A., Beauchamp, M. H., Clyman, R. I., Peri, K., Varma, D. R., Chemtob, S. (2001) Prostanoid receptors: ontogeny and implications in vascular physiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1343-R1360.
35. Nanni, P., de Giovanni, C., Lollini, P. L., Nicoletti, G., Prodi, G. (1983) TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1, 373-380.
36. Giovarelli, M., Santoni, A., Forni, G. (1985) Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity. J. Immunol. 135, 3596-3603.
37. Ferrantini, M., Giovarelli, M., Modesti, A., Musiani, P., Modica, A., Venditti, M., Peretti, E., Lollini, P. L., Nanni, P., Forni, G., et al. (1994) IFN-α 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-γ-producing TS/A cells. J. Immunol. 153, 4604-4615.
38. Cavallo, F., Signorelli, P., Giovarelli, M., Musiani, P., Modesti, A., Brunda, M. J., Colombo, M. P., Forni, G. (1997) Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89, 1049-1058.
39. Miller, F. R., Miller, B. E., Heppner, G. H. (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3, 22-31.
40. Pulaski, B. A., Ostrand-Rosenberg, S. (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58, 1486-1493.
41. Aslakson, C. J., Miller, F. R. (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405.
42. Rakhmilevich, A. L., Janssen, K., Hao, Z., Sondel, P. M., Yang, N. S. (2000) Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T- cell-independent mechanism. Cancer Gene Ther. 7, 826-838.
43. Plevy, S. E., Gemberling, J. H., Hsu, S., Dorner, A. J., Smale, S. T. (1997) Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17, 4572-4588.
44. Grazia Cappiello, M., Sutterwala, F. S., Trinchieri, G., Mosser, D. M., Ma, X. (2001) Suppression of IL-12 transcription in macrophages following Fc γ receptor ligation. J. Immunol. 166, 4498-4506.
45. Ma, X., Chow, J. M., Gri, G., Carra, G., Gerosa, F., Wolf, S. F., Dzialo, R., Trinchieri, G. (1996) The interleukin 12 p40 gene promoter is primed by interferon γ in monocytic cells. J. Exp. Med. 183, 147-157.
46. Schreiber, E., Matthias, P., Muller, M. M., Schaffner, W. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17, 6419,
47. Ma, X., Neurath, M., Gri, G., Trinchieri, G. (1997) Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J. Biol. Chem. 272, 10389-10395.
48. Cao, S., Liu, J., Chesi, M., Bergsagel, P. L., Ho, I. C., Donnelly, R. P., Ma, X. (2002) Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J. Immunol. 169, 5715-5725.
49. Simonson, M. S., Herman, W. H., Dunn, M. J. (1994) PGE2 induces c-fos expression by a cAMP-independent mechanism in glomerular mesangial cells. Exp. Cell Res. 215, 137-144.
50. Lacroix, S., Vallieres, L., Rivest, S. (1996) c-Fos mRNA pattern and corticotropin-releasing factor neuronal activity throughout the brain of rats injected centrally with a prostaglandin of E2 type. J. Neuroimmunol. 70, 163-179.
51. Won, J. S., Suh, H. W., Kim, Y. H., Song, D. K., Huh, S. O., Lee, J. K., Lee, K. J. (1998) Prostaglandin E2 increases proenkephalin mRNA level in rat astrocyte-enriched culture. Brain Res. 60, 203-214.
52. Iwahashi, H., Takeshita, A., Hanazawa, S. (2000) Prostaglandin E2 stimulates AP-1-mediated CD14 expression in mouse macrophages via cyclic AMP-dependent protein kinase A. J. Immunol. 164, 5403-5408.
53. Roy, S., Charboneau, R., Cain, K., DeTurris, S., Melnyk, D., Barke, R. A. (1999) Deficiency of the transcription factor c-fos increases lipopolysaccharide-induced macrophage interleukin 12 production. Surgery 126, 239-247.
54. Roy, S., Charboneau, R., Melnyk, D., Barke, R. A. (2000) Interleukin-4 regulates macrophage interleukin-12 protein synthesis through a c-Fos mediated mechanism. Surgery 128, 219-224.
55. Olive, M., Krylov, D., Echlin, D. R., Gardner, K., Taparowsky, E., Vinson, C. (1997) A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J. Biol. Chem. 272, 18586-18594.
56. Wu, R. S., Kobie, J. J., Besselsen, D. G., Fong, T. C., Mack, V. D., McEarchern, J. A., Akporiaye, E. T. (2001) Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol. Immunother. 50, 229-240.
57. Herschman, H. R. (1991) Primary response genes induced by growth factors and tumor promoters. Annu. Rev. Biochem. 60, 281-319.
58. Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., Karin, M. (1991) Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354, 494-496.
59. Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., Woodgett, J. R. (1991) Phosphorylation of c-jun mediated by MAP kinases. Nature 353, 670-674.
60. Mechta, F., Lallemand, D., Pfarr, C. M., Yaniv, M. (1997) Transformation by ras modifies AP1 composition and activity. Oncogene 14, 837-847.
61. Dendorfer, U., Oettgen, P., Libermann, T. A. (1994) Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol. Cell. Biol. 14, 4443-4454.
62. Chen, C., Chen, Y. H., Lin, W. W. (1999) Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 97, 124-129.
63. Allport, V. C., Slater, D. M., Newton, R., Bennett, P. R. (2000) NF-κB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol. Hum. Reprod. 6, 561-565.
64. Subbaramaiah, K., Lin, D. T., Hart, J. C., Dannenberg, A. J. (2001) Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J. Biol. Chem. 276, 12440-12448.
65. Subbaramaiah, K., Norton, L., Gerald, W., Dannenberg, A. J. (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277, 18649-18657.
66. Xin, Z., Sriram, S. (1998) Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J. Neuroimmunol. 89, 206-212.
67. Delgado, M., Ganea, D. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor κB and Ets activation. J. Biol. Chem. 274, 31930-31940.
68. Hoeffler, J. P., Meyer, T. E., Yun, Y., Jameson, J. L., Habener, J. F. (1988) Cyclic AMP-responsive DNA-binding protein: structure based on a cloned placental cDNA. Science 242, 1430-1433.
69. Foulkes, N. S., Borrelli, E., Sassone-Corsi, P. (1991) CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 64, 739-749.
70. Molina, C. A., Foulkes, N. S., Lalli, E., Sassone-Corsi, P. (1993) Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75, 875-886.
71. Bodor, J., Bodorova, J., Gress, R. E. (2000) Suppression of T cell function: a potential role for transcriptional repressor ICER. J. Leukoc. Biol. 67, 774-779.
72. Zhu, C., Rao, K., Xiong, H., Gagnidze, K., Li, F., Horvath, C., Plevy, S. (2003) Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP. J. Biol. Chem. 278, 39372-39382.
73. Smits, H. H., van Rietschoten, J. G., Hilkens, C. M., Sayilir, R., Stiekema, F., Kapsenberg, M. L., Wierenga, E. A. (2001) IL-12-induced reversal of human Th2 cells is accompanied by full restoration of IL-12 responsiveness and loss of GATA-3 expression. Eur. J. Immunol. 31, 1055-1065.
74. Taketo, M. M. (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 90, 1529-1536.
75. Taketo, M. M. (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 90, 1609-1620.
76. Kundu, N., Yang, Q., Dorsey, R., Fulton, A. M. (2001) Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int. J. Cancer 93, 681-686.
77. Yakar, I., Melamed, R., Shakhar, G., Shakhar, K., Rosenne, E., Abudarham, N., Page, G. G., Ben-Eliyahu, S. (2003) Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann. Surg. Oncol. 10, 469-479.
78. Ostrand-Rosenberg, S., Clements, V. K., Terabe, M., Park, J. M., Berzofsky, J. A., Dissanayake, S. K. (2002) Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-γ dependent. J. Immunol. 169, 5796-5804.
79. Massague, J. (1998) TGF-β signal transduction. Annu. Rev. Biochem. 67, 753-791.
80. Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., Koteliansky, V., Arteaga, C. L. (2002) Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559.
81. Cavallo, F., Di Carlo, E., Butera, M., Verrua, R., Colombo, M. P., Musiani, P., Forni, G. (1999) Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res. 59, 414-421.